Abstract: Cloning and expression of the gene encoding human phosphlipase inhibitory protein (hPIP) permits production of an anti-inflammatory protein in practical quantities using recombinant techniques.
Abstract: Methods, compounds and compositions are provided for inducing natriuresis, diuresis and vasodilatation in mammalian hosts by administering atrial natriuretic/vasodilator peptides to said host. Also provided are methods for producing such peptide compounds.
Type:
Grant
Filed:
April 28, 1992
Date of Patent:
November 2, 1993
Assignee:
Scios Nova, Inc.
Inventors:
John A. Lewicki, Robert M. Scarborough, Jr.
Abstract: Methods are provided for the isolation and purification of recombinant lung surfactant protein. The methods involve a multistep procedure including extraction with a C.sub.1 -C.sub.4 aliphatic alcohol and chromatographic purification steps which employ a C.sub.1 -C.sub.4 aliphatic alcohol as eluant. Purified proteins obtained using the disclosed isolation and purification steps are provided as well.
Type:
Grant
Filed:
July 10, 1990
Date of Patent:
November 2, 1993
Assignee:
Scios Nova Inc.
Inventors:
Bradley J. Benson, Douglas Buckley, David Lesikar, Asha Naidu, Kate B. Silverness
Abstract: An unexpectedly more potent isomer of 2-amino-4,5-(1,2-cyclohexyl)-7-phosphonoheptanoic acid, a known excitatory amino acid antagonist, pharmaceutical compositions including this isomer and methods of using this isomer to antagonize excitatory amino acid receptors.
Abstract: 5,6,7,8,9,10-Hexahydro-7,10-iminocyclohept[b]indole, 6,7,8,9,10,11-hexahydro-7,11-imino-5H-cyclooct[b]indole and substituted derivatives are effective in the treatment of psychoses with limited liability to produce concomitant adverse extrapyramidal symptoms. These compounds are also useful for treating other central nervous system and cardiovascular disorders.
Type:
Grant
Filed:
March 13, 1992
Date of Patent:
October 5, 1993
Assignee:
Scios Nova Inc.
Inventors:
Richard E. Mewshaw, Carl Kaiser, Mary E. Abreu
Abstract: Branched polyanhydrides that have superior properties for use in the controlled delivery of substances, prepared by the polymerization of a dicarboxylic acid monomer and a branching agent. The branching agent is a polycarboxylic acid monomer such as 1,3,5-benzenetricarboxylic acid ("BTC"), or an oligomerized fatty acid trimer. Alternatively, the branching agent is a polycarboxylic acid polymer such as poly(acrylic acid) ("PAA"). These branched polymers have significantly higher molecular weights and lower specific viscosity than linear polymers prepared under similar conditions. A major advantage of branched polyanhydrides is that the degradation and release kinetics can be substantially altered without significantly changing the physical properties of the polymer relative to the corresponding linear polymer. By manipulating both the diacid and the branching agent, a wide variety of biodegradable controlled delivery devices for diverse applications can be prepared.
Abstract: A local anesthetic microsuspension system is disclosed that includes lipospheres, that are solid, water-insoluble microparticles that have a layer of a phospholipid embedded on their surface. The core of the liposphere is a solid anesthetic such as lidocaine or marcaine, or an anesthetic dispersed in an inert solid vehicle, such as a wax. Anesthetic lipospheres provide a controlled delivery of local anesthetics to achieve extended, effective relief from pain by slowly releasing the anesthetic from the solid hydrophobic core. This is highly preferred over the situation in which an aqueous solution of local anesthetic must be frequently administered because it is quickly systemically absorbed.
Abstract: DNA sequences encoding .beta.-amyloid-related proteins associated with Alzheimer's disease are disclosed. Also provided herein is a DNA sequence encoding a novel protease inhibitor. These sequences are used in producing or constructing recombinant .beta.-amyloid core protein, .beta.-amyloid-related proteins and recombinant or synthetic immunogenic peptides. Antibodies generated against the recombinant proteins or immunogenic peptides derived therefrom can be used for cerebral fluid or serum protein diagnosis of Alzheimer's disease.
Type:
Grant
Filed:
June 6, 1989
Date of Patent:
June 29, 1993
Assignee:
Scios Nova Inc.
Inventors:
James W. Schilling, Jr., Phyllis A. Ponte, Barbara Cordell
Abstract: The present invention provides an in vitro tissue culture-based assay for amyloid deposition specific for Alzheimer's disease which is suitable for routine drug screening analysis. Immunological diagnostic reagents for Alzheimer's disease are also provided.
Abstract: A microsuspension system containing insect repellent is disclosed that includes lipospheres, that are solid, water-insoluble microparticles that have a layer of a phospholipid embedded on their surface. The core of the liposphere is a solid insect repellent, or an insect repellent dispersed in an solid vehicle, such as a wax. Insect repellents include compounds that repel insects, are insecticidal, or regulate or inhibit insect growth on humans and other animals and plants. Insect repellent lipospheres provide controlled release of insect repellents while minimizing absorption through the skin.
Abstract: Isolated DNA sequences, expression vectors and transformant cells are provided which allow for the large scale production of vascular endothelial cell growth factor. The vascular endothelial cell growth factor is useful in the treatment of wounds in which neovascularization or reendothelialization is required for healing.
Type:
Grant
Filed:
July 27, 1990
Date of Patent:
June 15, 1993
Assignee:
Scios Nova Inc.
Inventors:
Edmund G. Tischer, Judith A. Abraham, John C. Fiddes, Richard L. Mitchell
Abstract: DNA sequences encoding the beta-amyloid core protein, and beta-amyloid-related proteins associated with Alzheimer's disease are disclosed. These sequences are used in producing or constructing recombinant beta-amyloid core protein, beta-amyloid-related proteins and recombinant or synthetic immunogenic peptides. These sequences are also used to identify genomic mutations and/or restriction site alterations which are associated with a predisposition to Alzheimer's disease, for purposes of genetic screening. Antibodies generated against the recombinant proteins or immunogenic peptides derived therefrom can be used for cerebral fluid or serum protein diagnosis of Alzheimer's disease.
Abstract: Pharmaceutical formulations and a method for their preparation are provided. These formulations provide a stabilized basic fibroblast growth factor (bFGF) which is less susceptible to oxidation or metal-induced aggregation by including an amount of a chelating agent effective to stabilize the bFGF.
Type:
Grant
Filed:
April 4, 1990
Date of Patent:
June 8, 1993
Assignee:
Scios Nova Inc.
Inventors:
Linda Foster, Stewart A. Thompson, S. Joseph Tarnowski
Abstract: Methods, compounds and compositions are provided for inducing natriuresis, diuresis and vasodilatation in mammalian hosts by administering atrial natriuretic/vasodilator peptides to said host. Also provided are methods for producing such peptide compounds.
Type:
Grant
Filed:
June 5, 1986
Date of Patent:
May 18, 1993
Assignee:
Scios Nova Inc.
Inventors:
John A. Lewicki, Robert M. Scarborough, Jr.
Abstract: An apparatus for cleaning air contaminated by paint sprays through the use of a water wash system. The paint separation compartment comprises a collection plate for directing water droplets into a main water tank, the droplets having paint therein. The apparatus also having mist arrestor and charcoal filters. The contaminated air enters at a lower end of the apparatus and cleansed or purified air is exhausted from the upper end of the apparatus.